UBS Group AG lessened its holdings in shares of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) by 53.7% in the first quarter, Holdings Channel.com reports. The firm owned 14,560 shares of the specialty pharmaceutical company’s stock after selling 16,899 shares during the period. UBS Group AG’s holdings in Adamas Pharmaceuticals were worth $43,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. California Public Employees Retirement System acquired a new position in shares of Adamas Pharmaceuticals in the 4th quarter worth approximately $61,000. Citigroup Inc. increased its holdings in shares of Adamas Pharmaceuticals by 21.5% in the 4th quarter. Citigroup Inc. now owns 22,279 shares of the specialty pharmaceutical company’s stock worth $84,000 after acquiring an additional 3,938 shares during the period. Barclays PLC increased its holdings in shares of Adamas Pharmaceuticals by 81.1% in the 4th quarter. Barclays PLC now owns 23,439 shares of the specialty pharmaceutical company’s stock worth $90,000 after acquiring an additional 10,494 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Adamas Pharmaceuticals in the 4th quarter worth about $91,000. Finally, AQR Capital Management LLC acquired a new position in Adamas Pharmaceuticals during the 4th quarter valued at about $181,000. Hedge funds and other institutional investors own 55.33% of the company’s stock.
NASDAQ:ADMS opened at $2.51 on Wednesday. The company has a current ratio of 5.61, a quick ratio of 5.38 and a debt-to-equity ratio of 6.72. Adamas Pharmaceuticals Inc has a 1 year low of $1.90 and a 1 year high of $7.78. The firm’s fifty day simple moving average is $2.79 and its 200 day simple moving average is $3.83. The firm has a market capitalization of $73.21 million, a PE ratio of -0.76 and a beta of 1.69.
Adamas Pharmaceuticals (NASDAQ:ADMS) last released its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.77) by $0.18. Adamas Pharmaceuticals had a negative net margin of 160.44% and a negative return on equity of 806.54%. The company had revenue of $14.48 million during the quarter, compared to analysts’ expectations of $15.07 million. As a group, analysts anticipate that Adamas Pharmaceuticals Inc will post -2.11 EPS for the current fiscal year.
Several equities analysts have recently weighed in on ADMS shares. William Blair restated a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Friday, June 5th. Needham & Company LLC reissued a “hold” rating on shares of Adamas Pharmaceuticals in a research report on Friday, May 8th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Adamas Pharmaceuticals in a research report on Friday, June 5th. Finally, Zacks Investment Research lowered shares of Adamas Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, June 19th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company. Adamas Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $14.53.
Adamas Pharmaceuticals Profile
Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
Read More: Price to Earnings Ratio (PE)
Want to see what other hedge funds are holding ADMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Adamas Pharmaceuticals Inc (NASDAQ:ADMS).
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.